Patents Examined by Terra C. Gibbs
  • Oligomeric compounds comprising bicyclic nucleotides and uses thereof
    Patent number: 10337007
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: July 2, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Eric E. Swayze
  • Composition for reducing cellular senescence level including activity inhibitor inhibiting DCUN1D3 activity or expression inhibitor inhibiting expression of DCUN1D3-encoding gene and use thereof
    Patent number: 10329569
    Abstract: Provided is a composition and method for reducing a cellular senescence level by inhibiting the activity or expression of one or more of DCUN1D3 protein or gene encoding same and a polynucleotide having a nucleotide sequence of SEQ ID NO: 5, as well as a method of treating a disease or a disease symptom associated with an increased cellular senescence level in a mammal.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: June 25, 2019
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Myoungsoon Kim, Yongsub Kim, Young-Sam Lee
  • Compositions and methods for reducing neointima formation
    Patent number: 10328182
    Abstract: Compositions, devices, grafts and methods for reducing or preventing anti-neointima following cardiovascular injuries and interventions are disclosed. The compositions, devices, and grafts typically include an effective amount of a CTP synthase 1 inhibitor to reduce proliferation of vascular smooth muscle cells, without substantial reducing the proliferation of endothelial cells. Methods of reducing neointima formation, accelerating re-endothelialization, and reducing restenosis in a subject using the compositions, devices, and grafts are also disclosed.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: June 25, 2019
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: Shiyou Chen, Rui Tang
  • Compositions for modulating Ataxin 2 expression
    Patent number: 10308934
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Ataxin 2 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotropic sclerosis (ALS), and parkinsonism.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: June 4, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Susan M. Freier
  • Targeting human satellite II (HSATII)
    Patent number: 10301624
    Abstract: Methods for treating cancer, e.g., cancer of epithelial origin, by specifically targeting human satellite II (HSATII) using sequence specific agents such as oligonucleotides. As shown herein, the hetero chromatic HSATII satellite repeat is silenced in normal cells, but massively over expressed in epithelial cancers and in cancer cell lines when grown as xenografts or in 3D culture. Induction of HSATII RNA, either in xenografts or using in vitro reconstitution models, suggests the appearance of complementary DNA intermediates.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: May 28, 2019
    Assignees: The General Hospital Corporation, Aalborg University
    Inventors: David T. Ting, Daniel A. Haber, Shyamala Maheswaran, Francesca Bersani, Anders M. Naar, Mihir Shivadatta Rajurkar, Sakari Kauppinen, Andreas Petri
  • Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (SNA)
    Patent number: 10301622
    Abstract: The present invention relates to methods of detecting and tracking a target molecule using a nanoparticle wherein the nanoparticle comprises a polynucleotide that can specifically associate with the target molecule, and wherein the association results in a change in a detectable marker that can be measured after association with the target molecule.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: May 28, 2019
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Chad A. Mirkin, William E. Briley, Pratik S. Randeria, Nathaniel J. Kim
  • Targeting microRNAs for metabolic disorders
    Patent number: 10287589
    Abstract: Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluceoneogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level. In certain embodiments, the methods comprise inhibiting the activity of miR-103. In certain embodiments, the methods comprise inhibiting the activity of miR-107. In certain embodiments, the activity of both miR-103 and miR-107 is inhibited. In certain embodiments, such methods comprise administering a compound comprising an oligonucleotide targeted to a microRNA.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: May 14, 2019
    Assignee: ETH Zurich
    Inventors: Markus Stoffel, Mirko Trajkovski
  • Compositions and methods for correcting limb girdle muscular dystrophy type 2C using exon skipping
    Patent number: 10273483
    Abstract: The invention is directed to one or more antisense polynucleotides and their use in pharmaceutical compositions in a strategy to induce exon skipping in the ?-sarcoglycan gene in patients suffering from Limb-Girdle Muscular Dystrophy-2C (LGM-D2C) or in patients at risk of such a disease. The invention also provides methods of preventing or treating muscular dystrophy, e.g., LGMD2C, by exon skipping in the gamma sarcoglycan gene using antisense polynucleotides. Accordingly, in some aspects the invention provides an isolated antisense oligonucleotide, wherein the oligonucleotide specifically hybridizes to an exon target region of a ?-sarcoglycan RNA. In another aspect, the invention provides a method of inducing exon-skipping of a gamma sarcoglycan RNA, comprising delivering an antisense oligonucleotide or a composition to a cell.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: April 30, 2019
    Assignees: THE UNIVERSITY OF CHICAGO, NORTHWESTERN UNIVERSITY
    Inventors: Elizabeth McNally, Eugene Wyatt
  • Compositions and methods for inhibition of expression of protein C (PROC) genes
    Patent number: 10273478
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting a PROC gene, and methods of using the dsRNA to inhibit expression of PROC.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: April 30, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Ivanka Toudjarska, John M. Maraganore, Brian Bettencourt, Stuart Milstein, Martin A. Maier, Klaus Charisse, Kallanthottathil Rajeev, Satyanarayana Kuchimanchi
  • Method and composition for diagnosis or treatment of aggressive prostate cancer
    Patent number: 10273546
    Abstract: Methods, pharmaceutical formulations and medicaments for treating prostate cancer or preventing the progression of a nonaggressive form of prostate cancer to an aggressive form, in a mammal, include a therapeutically effective amount of one or more active agents that reduce the expression or biological activity of both Forkhead box protein M1 (FOXM1) and Centromere protein F (CENPF) or biologically active fragments thereof or biologically active fragments thereof selected from the group consisting of an isolated shRNA, siRNA, antisense RNA, antisense DNA, Chimeric Antisense DNA/RNA, microRNA, and ribozymes that are sufficiently complementary to either a gene or an mRNA encoding either FOXM1 or CENPF proteins. A method is also presented for discovering synergistic master regulators of other phenotype transitions, wherein the master regulators are conserved among different species.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: April 30, 2019
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Corinne Abate-Shen, Andrea Califano, Michael Shen
  • Use of aptamers in therapy and/or diagnosis of autoimmune diseases
    Patent number: 10266830
    Abstract: The present invention is directed to an aptamer comprising or consisting of the nucleic acid sequence of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and/or a nucleic acid sequence being at least 80% identical to one of SEQ ID No. 1, 2 and 3 for use in therapy and/or diagnosis of autoimmune diseases, wherein the autoimmune disease is cardiomyopathy, dilated cardiomyopathy (DCM), peripartum cardiomyopathy (PPCM), idiopathic cardiomyopathy, Chagas' cardiomyopathy, Chagas' megacolon, Chagas' megaesophagus, Chagas' neuropathy, benign prostatic hyperplasia, scleroderma, psoriasis, Raynaud syndrome, pre-eclampsia, kidney allograft rejection, myocarditis, glaucoma, hypertension, pulmonary hypertension, malignant hypertension, and/or Alzheimer's disease.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: April 23, 2019
    Assignees: Max-Delbrueck-Centrum fuer Molekulare Medizin, Charite-Universitaetsmedizin Berlin
    Inventors: Ingolf Schimke, Annekathrin Haberland, Gerd Wallukat
  • RNAi inhibitors of glucose-6-phosphate dehydrogenase for treating cardiovascular and pulmonary conditions
    Patent number: 10246711
    Abstract: The present disclosure provides for methods of treating or preventing a cardiovascular disorder and/or a related pulmonary disorder in a subject. In certain embodiments, a therapeutically effective amount of a polynucleotide inhibitor of Glucose-6-phosphate dehydrogenase (G6PD) or a nucleic acid encoding G6PD is administered.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: April 2, 2019
    Inventor: Rakhee Gupte
  • RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
    Patent number: 10246714
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against CTNNB1 gene expression.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: April 2, 2019
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Duncan Brown, James J. Cunningham, Marian Gindy, Victoria Pickering, Matthew G. Stanton, Steven M. Stirdivant, Walter R. Strapps
  • Angiotensinogen (AGT) iRNA compositions and methods of use thereof
    Patent number: 10238749
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: March 26, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Donald Foster, Brian Bettencourt, Klaus Charisse, Gregory Hinkle, Satyanarayana Kuchimanchi, Martin Maier, Stuart Milstein
  • MicroRNA assay for detection and management of pancreatic cancer precursors
    Patent number: 10240208
    Abstract: The current invention pertains to miRNAs that are differentially expressed in samples of an individual having pancreatic cancer, or having a high risk of developing pancreatic cancer, as compared to the corresponding sample of an individual not having pancreatic cancer, or having low risk of developing pancreatic cancer, respectively. In certain embodiments, the miRNAs are differentially expressed in a tissue sample or blood plasma sample of an individual having a pancreatic lesion and having a high risk of developing pancreatic cancer as compared to the corresponding tissue sample or blood sample of an individual having the pancreatic lesion and having no risk or low risk of developing pancreatic cancer. These differentially expressed miRNAs can be used as biomarkers for diagnosis, treatment, and/or prevention of pancreatic cancer, particularly, in a subject having a pancreatic lesion.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: March 26, 2019
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: Mokenge P. Malafa, Jennifer Permuth, Dung-Tsa Chen
  • Neurotensin-induced tumor formation is regulated by micro RNA 133A-aftiphilin-dependent receptor recycling
    Patent number: 10233463
    Abstract: This application discloses methods of treating, preventing, and diagnosing colorectal cancer and IBD in a subject comprising administering an effective dose of antisense miR-133? or AFTPH to the subject or detecting expression levels of miR-133? and AFTPH.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: March 19, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Charalabos Pothoulakis, Dimitrios Iliopoulos, Ka Man Law
  • Method of regulating gene expression
    Patent number: 10233451
    Abstract: The present invention relates, in general, to gene expression and, in particular, to a method of inhibiting the expression of a target gene and to constructs suitable for use in such a method.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: March 19, 2019
    Assignee: Duke University
    Inventors: Bryan R. Cullen, Yan Zeng
  • Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
    Patent number: 10208307
    Abstract: The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: February 19, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Tracy Zimmermann, Amy Chan, Vasant Jadhav, Martin Maier, Kallanthottathil G. Rajeev
  • C/EBP? short activating RNA compositions and methods of use
    Patent number: 10202601
    Abstract: The invention relates to saRNA targeting a C/EBP? transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: February 12, 2019
    Assignee: MiNA THERAPEUTICS LIMITED
    Inventor: Pål Sætrom
  • Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
    Patent number: 10201556
    Abstract: The invention relates to the therapeutic use of a combination in a disease and condition associated with melanoma or a disease or a condition associated with activated BRAF pathway.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: February 12, 2019
    Assignee: INTERNA TECHNOLOGIES B.V.
    Inventors: Rick Jan van Haastert, Petronella Innocentia van Noort, Grégoire Pierre André Prevost, Willemijn Maria Gommans, Roeland Quirinus Jozef Schaapveld, Matheus Maria De Gunst, Iman Johannes Schultz, Eugene Berezikov